§

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Lichtenberger, Lenard M.

SERIAL NO: 09/827,493 FILED:

§ 04/06/01 § §

FOR: Unique Composition of Zwitterionic Phospholipids and Bisphosphonates with Reduced Toxicity and Enhanced §

Bioavailability

EXAMINER: JIANG

GROUP ART UNIT: 1617

DOCKET: 96606/15UTL

EV 123 140 689 US Number

CERTIFICATE OF MAIL BY EXPRESS MAIL

October 18, 2002

Date of Deposi ertify that this paper or fee is being deposited with the United States Postal Service "Express Mail

ge under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the: **Assistant Commissioner of Patent**

Washington, D.C. 20231

October 18, 2002 Date of Signature

RESPONSE TO 13 AUGUST 2002 FINAL OFFICE ACTION

Dear Examiner:

In response to the Final Office Action dated 13 August 2002 Applicants submit the following amendments and remarks:

SUMMARY OF NON-FINAL OFFICE ACTION

	Election/Restriction
Claims 1-32	103(a) obvious Daifotis et al. + Lichtenberger

REMARKS

Applicants intend this response to be a complete response to the Examiner's 13 August 2002 Final Office Action. Applicants have numbered the paragraphs in their response to correspond to the paragraph numbering in the Office Action for the convenience of the Examiner.

Claim Rejections - 35 USC § 103(a)

Claims 1-32 stand and remain rejected under 35 U.S.C. 103(a) as being unpatentable over Daifotis, et al. (WO 9904773) in view of Lichtenberger et al., essentially for reasons of